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Summary A study has been carried out in which a comparison was made between EU lymphoma (assumed
to be an insulin-producing secreting tumour) and thymoma (an insulin-dependent tumour). Tumour develop-
ment and incidence, 3H-thymidine incorporation and insulin content in tumours, the host's food intake, blood
insulin, glucose and cholesterol were determined in non-diabetic and alloxan-diabetic mice. Whereas no
significant differences were observed between the diabetic and non-diabetic EL4 tumour-bearing mice, the
diabetic, thymoma tumour-bearing mice showed reduced tumour growth and lower tumour incidence as
compared with their non-diabetic counterparts. Insulin administration to diabetic tumour bearing mice,
enhanced 3H-thymidine incorporation in the thymoma tumour cells only, and the insulin content of the EM
tumours was found to be higher than that of the thymoma tumours. Rapid diabetes remission was observed in
the diabetic, EL4 tumour-bearing mice as compared with the thymoma tumour-bearing mice.
The involvement of insulin in malignancies is manifested in
various ways such as increasing the uptake of glucose and
other nutrients by cancer cells (Jehl et al., 1955) and
stimulating DNA synthesis (Heuson et al., 1972; Lupulescu,
1983; Cohen & Hilf, 1974). Disturbed glucose metabolism
associated with hyperinsulinaemia in lung cancer patients and
insulin resistance in other types of cancer is well documented
(Bernshtein et al., 1985; Copeland et al., 1987; Lundholm et
al., 1978). Confficting observations have been reported regar-
ding blood cholesterol and its possible relationship to cancer
(De Waard, 1975; Fernleib 1983; McMichael et al., 1984).
Diabetes mellitus of type I, (deficient in insulin secretion) and
type II (non-insulin-dependent diabetes mellitus) are
generally associated with high plasma cholesterol level, des-
pite low cholesterol synthesis. This phenomenon may be due
to a decreased rate of cholesterol catabolism (Harper, 1965;
Stolar, 1988).
This study is an attempt to secure more information on the
relationship between cholesterol, glucose and insulin-tumours
in mice bearing different tumours (EM or thymoma). The
response of blood insulin, glucose, total cholesterol, food and
water intake, body weight and tumour insulin content and
thymidine incorporation after tumour transplantation, were
studied in normal and alloxan-induced diabetic mice.
Materials and methods
Animals, diet and tumours
C57BL/6J male mice were used in all experiments (purchased
from Jaxson Laboratory, Pearl Harbor, Maine, USA) which
were kept in filter covered plastic cages (six mice per cage)
and fed ad lib. with chow pellets formulated according to the
National Research Council (1978). EM or thymoma tumour
cell were randomly injected into the right flank muscle at
22-26 weeks of age.
Tumour cells EL4 cells (C57BL/6J lymphoma) were main-
tained by serial passage in the flank of the mice. Thymoma
.cells produced according to Haran-Ghera et al. (1977) were
provided by A. Peled, Weizmann Institute of Science.
Tumour cell suspensions were washed three times with phos-
phate buffered saline (PBS) by centrifugation. The cell
viability was ascertained by trypan blue exclusion, 0.2 x 106
cells were injected for the EL4 tumour, whereas 1.5 x 106
cells were used for the thymoma tumour.
Diabetes was induced by i.v. injection of 1Omg 100 g'
body weight (BW) Monohydric Alloxan (Sigma), 7 days
before tumour transplantation. In experiments 2 and 3,
glucosuria was checked by Clinistix-strips (Ames, UK) 4 days
after alloxan administration, and only mice showing
glucosuria were included in the experiment.
The early incidence of tumour was determined by positive
or negative palpation.
Chemical analyses
Since the amount of blood obtained from a single mouse was
insufficient for all determinations, blood collected from 10
mice was pooled, part of which was transferred to pre-cooled
centrifuge tubes containing fluoride oxalate and centrifuged
(1,500 r.p.m. for 10 min). The plasma glucose was determined
by the glucose oxidase procedure on the same day, according
to Pennock et al. (1973).
After coagulation (2 h, 5C) the blood was centrifuged and
the serum collected and frozen. Insulin level was determined
in the pooled serum and in cell-free tissue extract which was
prepared as follows: a weighed sample of tissue was tri-
turated on a plastic net in PBS, centrifuged (2,000 g, 30 min,
5C, and the supernatant collected and frozen at - 20C.
Insulin was determined by a double antibody radio immuno-
assay, using '25I-labelled human insulin (Pharmacia Diagnos-
tics AB, Uppsalla, Sweden). Total cholesterol was determined
in serum by an enzymatic colorimetric method according to
Siedel et al. (1983) (Monotest Cholesterol, Bohringer Mann-
heim, GmbH. Diagnostica).
Experiment 1: non-diabetic mice
In each trial seventeen cages containing six mice each were
allocated to the control, ETA and thymoma groups respec-
tively. Three consecutive trials were performed (i.e. 6
mice x 17 cages x 3 treatments x 3 trials) on a total of 918
mice. Tumour transplantation was carried out as described
above. Body weight and food intake were determined each
day. Ten mice per group selected randomly (a total of 30
mice per period) 0, 4, 11, 14, 16, 20 and 24 days after
transplantation, were guillotined and had their blood col-
lected immediately. Tumour incidence was estimated on the
remaining mice every other day after tumour transplantation
until day 20. Because of the early high mortality rate in the
EL4 tumour bearing mice, the last determination in this
treatment was carried out 16 days after tumour transplanta-
tion.
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Experiment 2: diabetic mice
The experimental procedure was essentially the same as in
experiment 1. Seven days before tumour transplantation
diabetes was induced by alloxan injection. Mice were killed 0,
5, 12 and 20 days after tumour transplantation and, as in
experiment 1, the last determination in the EL4 group was
done 12 days after transplantation. In this experiment water
intake was also determined. Insulin in tumours was deter-
mined 12 and 16 days after tumour transplantation in the
EL4 and thymoma mice respectively.
Experiment 3
Diabetic mice were produced by alloxan injection, one week
after which they were divided into four groups of five mice
each. EL4 cells were transplanted in two groups and
thymoma in the other two. Twelve days after EL4 transplan-
tation and 16 days after thymoma transplantation, one of the
tumour groups was injected subcutaneously with bovine
insulin (Novo Ind., Copenhagen, Denmark; 21 100 g-1), 48,
24 and 3 h before killing and 3H-thymidine was also
administered together with the last insulin injection
(5 iLCi g-' in 0.2 ml saline, NEN, specific activity
28.5 Ci mmol -). At killing insulin was determined in part of
the tumour tissue, and the remaining part and muscle from
the left flank were weighed and homogenised, using a fritted
glass Potter homogeniser. DNA was precipitated with 10%
perchloric acid and washed twice with ethanol. Radioactivity
was measured using a nuclear liquid scintillation system
(Packard Tricarb) and insulin concentration and thymidine
incorporation were also measured in the left flank of non-
diabetic, non-tumour-bearing mice (NTB).
Statistical analysis
The differences between the trial means in each treatment
group were tested for significance by one-way analysis of
variance.
Results
Experiment 1: non-diabetic mice
Food intake and body weight Body weight increased slightly
but consistently in non-tumour bearing mice (NTB), in which
food intake was constant during the experimental period
(Figure 1).
In the EL4 groups, tumour transplantation was followed
by a consistent drop in body weight. However, from the
second to the fourteenth days after transplantation, body
weight increased linearly according to tumour dimensional
growth and decreased thereafter, concomitantly with mor-
tality. Consistent fluctuations were observed in food intake
which decreased dramatically ten days after transplantation.
The thymoma groups displayed less effect after tumour
transplantation than was seen in the EL4 groups, and body
weight loss observed after tumour transplantation was
gradually compensated for and reached, or slightly exceeded
the weight of the control mice. Food intake exceeded that of
the control groups up to 18 days post-transplantation, after
which it dropped consistently.
Blood plasma glucose, serum insulin and cholesterol
Insulinaemia was much higher and glycaemia much lower in
the tumour bearing mice than in the NTB (Figure 2).
Insulinaemia tripled 4 days after transplantation, dropped
moderately at 10 days and increased further thereafter in the
EL4 groups, whereas in the thymoma mice, the increase was
gradual and attained a peak 20 days after transplantation. In
accordance with serum insulin level, plasma glucose was
reduced far more in the EL4 mice than in those bearing
thymoma.
Blood cholesterol gradually increased in the EL4 and
decreased in the thymoma mice. In the NTB groups, the
periodic variations were small and inconsistent (Figure 2).
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Figure 1 Body weight and food intake by time of non-diabetic
intact mice, or of non-diabetic mice after EL4 or thymoma
tumour transplantation. Within periods, values with different
letters differ to a statistically significant degree (P<0.05). Vertical
bars stand for the s.e.m. -.- Control. -4- EL4. - Thymoma.
Experiment 2: diabetic mice
Food and water intake and body weight In NTB mice, des-
pite the important increase in food intake, alloxan-induced
diabetes showed a consistent drop in body weight (Figure 3).
Tumour transplantation was accompanied by a dramatic
increase in body weight in the EL4 mice, and a more gradual
increase in the thymoma mice. Alloxan-induced hyperphagia
was gradually reduced after tumour transplantation to reach
normal intake at the end of the experimental period. Water
consumption was parallel to food intake, but doubled after
diabetes induction and, in the tumour-bearing mice,
gradually resumed the level observed before alloxan injection.
Bloodplasma glucose, serum insulin and cholesterol Alloxan
injection to NTB mice reduced insulinaemia by 60% (about
18;U ml-I in experiment 1 vs 6lU ml- in the present
experiment) and caused a dramatic increase in blood plasma
glucose level (425 vs 125 mg 100 ml-') (Figure 4). In the
tumour-bearing diabetic mice, although blood insulin level
was much higher than in the NTB counterparts, it was still
lower than in normal mice and increased faster in the EL4
than the thymoma groups.
Blood plasma glucose gradually decreased in the tumour-
bearing mice and reached almost normal levels 12 and 20
days after tumour transplantation in the EL4 and thymoma
mice respectively.
Alloxan-induced diabetes affected total blood cholesterol
very slightly when compared to the levels obtained in experi-
ment 1. The trends caused by tumour transplantation
observed in experiment 1 (i.e. increased cholesterolaemia in
the EL4 mice and decreased cholesterolaemia in the
thymoma mice) were repeated in the diabetic mice.
Whereas in EL4 mice, tumour incidence was not affected
by alloxan-induced diabetes, it was consistently reduced in
the diabetic thymoma mice as compared with non-diabetic
mice (Figure 7).
Experiment 3
Insulin concentration in tumours Insulin concentration in
tumours of EL4 diabetic mice was over 10 times that found
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Figure 3 Body weight food and water intake by time ofalloxan-
diabetic mice, or of alloxan-diabetic mice after EL4 or thymoma
tumour transplantation. Within periods, values with different
letters differ to a statistically significant degree (P<0.05). Vertical
bars stand for the s.e.m. -in- Control. -.- EL4. -A Thymoma.
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Figure 2 Blood insulin, glucose and total cholesterol of non-
diabetic intact mice, or of non-diabetic mice after EL4 or
thymoma tumour transplantation. Within periods, values with
different letters differ to a statistically significant degree
(P<0.05). Vertical bars stand for the s.e.m. -i- Control.
EL4. -A Thymoma.
in the muscle of the NTB non-diabetic mice and somewhere
in between in diabetic thymoma tumour mice. Insulin
administration was accompanied by a slight non-significant
reduction in the tumour insulin concentration of the tumour-
bearing mice (Figure 5).
3H-Thymidine incorporation in tumours Incorporation of 3H-
thymidine into the muscle was slightly higher (non-
significant) in the tumour-bearing mice than the controls
(Figure 6) and higher in the tumours of diabetic EL4 mice
than thymoma mice. Insulin administration was accompanied
by a dramatic increase in the incorporation of 3H-thymidine
in the tumour of thymoma mice but did not affect the EL4
mice.
Discussion
Numerous studies have emphasised the phenomenon of
'cancer glucose' hunger and diabetic hyperglycaemia should
therefore provide considerable advantages in cancer develop-
ment. However, Pavelic & Slyjepcevic (1978) reported that
murine thymoma grew more slowly in diabetic mice and that
such mice had a significantly longer survival period than the
non-diabetic controls. The authors suggest a tumour insulin-
dependency.
Thymoma tumour
The present study reinforces the above suggestion in the light
of lower tumour incidence observed in final stages (38 vs
90%) in diabetic than non-diabetic mice (Figure 7), as well as
the slower increase in tumour weight as reflected by body
weight (Figure 3), (the authors unpublished results indicate
that the weight of dissected tumours varied between 1 and
6 g and was related to body weight) and by the enhanced
thymidine incorporation into cancer cells after insulin admin-
istration (Figure 6).
A direct effect of alloxan on tumour cells does not seem to
account for these observations, since half its biological life is
only one hour (Rerup, 1968). Like thymoma, other tumours
have been reported to be insulin dependent. These are: MCF-
7 human breast cancer (Shafic & Liotta, 1980), respiratory
cancer in human male (Kesler, 1970), rat mammary
adenocarcinoma (Puckitt & Shagleton, 1972), or carcinoma
(Heuson & Legros, 1970), rat hepatoma (Salzberg & Griffin,
1952), rat Novikoff hepatoma (Goranson et al., 1954), rat
Walker carcinoma (Goranson & Tilser, 1955), murine mam-
mary carcinoma (Puckitt & Shagleton, 1972), Erlich tumour
(Pavelic et al., 1979), Erlich ascites carcinoma in mice (Fung
et al., 1985). Several of these tumours might cause remission
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Figure 4 Blood insulin, glucose and total cholesterol of alloxan-
diabetic mice, or of alloxan-diabetic mice after EL4 or thymoma
tumour transplantation. Within periods, values with different
letters differ to a statistically significant degree (P<0.05).
Vertical bars stand for the s.e.m., horizontal lines indicate the
level of normal non-diabetic mice (Figure 2). L Control.
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Figure 5 Insulin content in the muscle of intact mice and in the
tumour of alloxan-diabetic mice bearing EL4 or thymoma
tumour with or without insulin administration. Values with
different letters differ to a statistically significant degree
(P<0.05). Vertical bars stand for the s.e.m. Non-diabetic.
Diabetic. Diabetic + insulin.
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Figure 6 3H-Thymidine incorporation in the muscle of intact
mice and in the muscle and tumour of alloxan-diabetic mice
bearing EL4 or thymoma tumour with or without insulin
administration. Values with different letters differ to a statistically
significant degree (P<0.05). Vertical lines stand for the s.e.m.
Non-diabetic. M Diabetic. I Diabetic + insulin.
in the hosts' diabetes despite this dependency. Hyperg-
lycaemia in diabetic mice declined significantly after
thymoma, Erlich tumour, Walker 256 carcinoma or Novikoff
hepatoma transplantation (Pavelio & Slyjepcevic, 1978;
Goranson & Tilser, 1955; Pavelic et al., 1979). The increased
cell glucose uptake was attributed to the ability of these
tumours to stimulate insulin secretion from host pancreatic
P-cells (Pavelic & Slyjepcevic, 1978), and/or to maintain the
hormone, probably due to high receptor density. Other fac-
tors having insulin-like activity cannot be discounted and
remain undetermined.
The reduction in blood insulin observed 24 days after
transplantation in thymoma bearing mice (Figure 2), which
did not show a concomitant increase in plasma glucose, may
be due to less food intake and pancreatic insulin production,
accompanied by an increase in tumour glucose demands.
EL4 tumour
In the present study the EL4-bearing mice were characterised
by high blood insulin levels (even before tumour could be
detected (Figures 2 and 4) and by regular tumour develop-
ment, manifested by the increase in body weight (Figures 1
and 3) of diabetic as compared to non-diabetic mice.
Furthermore, earlier tumour detection in the diabetic mice
(Figure 7) suggests favourable conditions for tumour
development in its early stage.
High rate of diabetes remission (Figures 2 and 4),
enhanced thymidine incorporation in tumour cells, with or
without insulin administration (Figure 6), and high insulin
content in EL4 tumour tissue was also observed in non-
diabetic and alloxan-diabetic mice (Figure 5). Although these
observations suggest that EL4 is probably an insulin-
producing secreting tumour, direct proof of insulin produc-
tion by EL4 tumour cells remain undetermined. The absence
of hypoinsulinaemia in agonising mice (as compared to the
thymoma mice; Figure 2) reinforces this suggestion.
Many tumours have been reported to be insulin-producing/
secreting in humans, such as: insulinoma (Yoshinobu et al.,
1985), cervix carcinoma and corpus uteri carcinoma (Pavelic
et al., 1982a), mammary and bronchial carcinoma
(Greenberg et al., 1968), thoracic sarcomata and fibrosar-
coma (Linscheer et al., 1967), renal adenocarcinoma (Pavelic
& Pavelic, 1981). Hodgkin's and non-Hodgkin's lymphoma
(Pavelic et al., 1982b; Pavelic & Vuk-Pavlovic, 1983). The
above applies also to experimental animals: murine B16
melanoma (Bajzer et al., 1984), myeloid leukaemia (Graham,
1986) and aplastic carcinoma (Hyrayama, 1978). Hobbs &
Miller (1967) observed high insulin levels in such tumours.
Several authors have also observed high concentrations of
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insulin-like substances in the plasma of tumour-bearing
humans (Chowddhury & Bleicher, 1973; Shapot, 1972). It is
thought that hyperinsulinaemia evokes an 'insulin receptor
down regulation' (Baldwin et al., 1981; Mountjoy et al.,
1983), as well as a sharp decrease in the insulin binding
capacity (Gammeltoft, 1984), or disturbed glucose
metabolism and insulin resistance (Bernshtein et al., 1985;
Copeland et al., 1987; Lundholm et al., 1978). However, all
these phenomena are virtually absent in some human tumour
cells (Mountjoy et al., 1983, 1987), making them meta-
bolically superior to normal cells. The real significance of
these observations reveals that the host's blood nutrients, in
hyperinsulinaemic status, are more predisposed to tumour
cells than non-malignant normal cells.
Contradictory studies have been reported on the relation-
ship between blood cholesterol and cancer development. The
possible cholesterol involvement in cancer is indicated by the
fact that its oxidation products are known to be carcinogenic
(Bischoff, 1969) and mutagenic (Smith et al., 1979). Further
reports show that increased serum cholesterol is associated
with breast cancer which is more common in overweight
women (De Waard, 1975) and also associated with high
animal fat intake (Armstrong & Doll, 1975; Hems, 1978;
Miller et al., 1978; Drasar & Irving, 1973). Preliminary
analyses of data indicated that dietary cholesterol and fat are
significantly associated with human lung cancer risk (Kolonel
et al., 1981; Hinds et al., 1982) and cancer in mice (Szepsen-
wol, 1966). On the other hand, several recent epidemiological
studies have found serum cholesterol to be inversely related
to cancer risk in colon and gastric carcinoma incidence
(Fernleib, 1983; McMichael et al., 1984; Cambien et al.,
1980; Beaglehole et al., 1980; Kark et al., 1980). Other
studies have found no association (Dyer et al., 1981; Yaari et
al., 1981), and although several authors propose that
hypocholesterolaemia is a predisposing factor to cancer
development (Cambien et al., 1980), no causative relationship
has been so far established, which led Rose and Shipley
(1980), McMichael et al. (1984) and Alexopoulos et al. (1987)
to conclude that low plasma cholesterol is secondary to
malignant disease.
The present study, which has been carried out on two
different tumours, does not elucidate the relationship between
cholesterol and cancer. However, it is possible that since
cholesterol metabolism is profoundly affected by insulin
(Harper, 1965; Stolar, 1988), abnormal blood plasma
cholesterol in tumour-bearing subjects may be secondary to
abnormal insulin regulation and metabolism in malignancies.
Data on the insulin-cholesterol relationship are scarce,
especially in cancer-bearing subjects and merit further inves-
tigation. Additional data on insulin-tumour relationships
would enable a detailed classification of tumours and
host-tumour metabolic dependencies, which would lead to
more efficient preventive treatment and measures.
References
ALEXOPOULOS, C.G., BLASTIOS, B. & AVGERINOS, A. (1987). Serum
lipids and lipoprotein disorders in cancer patients. Cancer, 60,
3065.
ARMSTRONG, B.K, & DOLL, R. Environmental factors and cancer of
the colon and breast. Br. J. Cancer, 15, 617.
BAJZER, Z., PAVELIC, K. & VUK-PAVLOVIC, S. (1984). Growth self-
incitement in murine melanoma B16. A phenomenological model.
Science, 225, 930.
BALDWIN, D. Jr, PRICE, M., TSAI, P. & 4 others (1981). Insulin
binding internalization and receptor regulation in cultured human
fibroblasts. Am. J. Physiol., 241 E, 251.
BEAGLEHOLE, R., FOULKES, M.A., PRIOR, I.A.M. & EYLES, E.F.
(1980). Cholesterol and mortality in New Zealand Maoris. Br.
Med. J., i, 285.
BERNSHTEIN, L.M., BOBROV, Y.F., OSTROUMOVA, M.N. & 4 others
(1985). Relationship between lipidemia and insulinemia and body
fat level, body surface area and subcutaneous fat tissue. Condi-
tion in patients with cancer of the breast and lung. Vopr. Onkol.,
31, 44.
BISCHOFF, F. (1969). Carcinogenic effects of steroids. Adv. Lipid
Res., 7, 165.
CAMBIEN, F., DUCIMITIERE, A. & RICHARD, J. (1980). Total serum
cholesterol and cancer mortality in a middle ages male popula-
tion. Am. J. Epidemiol., 112, 388.
CHOWDDHURY, F. & BLEICHER, S.J. (1973). Studies of tumour
hypoglycemia. Metabolism, 22, 663.
COHEN, N.D. & HILF, R. (1974). Influence of insulin on growth and
metabolism of dimethylbenz(a)anthracene induced mammary
tumours. Cancer Res., 34, 3245.
COPELAND, G.P., LEINSTER, S.J., DAVIS, J.C. & HEPKIN, L.J. (1987).
Insulin resistance in patients with cholesterol cancer. Br. J. Surg.,
74, 1031.
DE WAARD, F. (1975). Breast cancer incidence and nutritional status
with particular reference to body weight and height. Cancer Res.,
35, 3351.
DRASAR, B.S. & IRVING, D. (1973). Environmental factors and
cancer of colon and breast. Br. J. Cancer, 27, 167.
DYER, A.R., STAMLER, J., OGLESBY, P. & 7 others (1981). Serum
cholesterol and risk of death from cancer and other causes in
three Chicago-epidemiological studies. J. Chronic Dis., 34, 249.
FERNLEIB, M. (1983). Review of the epidimiological evidence for a
possible relationship between hypocholesterolemia and cancer.
Cancer Res., 43, 2503.
FUNG, K.P., CHAN, T.W. & CHOY, Y.M. (1985). Suppression of Erlich
ascites tumour growth in mice by starvation and streptozotocin
induced diabetes. Cancer Lett., 28, 273.
GAMMELTOFT, S. (1984). Insulin receptors, binding kinetics and
structure function relationship of insulin. Physiol. Rev., 64, 1321.
GORANSON, E.S., BOTHAM, F. & WILLM, M. (1954). Inhibition of
growth of transplantable alloxinated Wistar rats. Cancer Res., 14,
730.
GORANSON, E.S. & TILSER, G.J. (1955). Studies on the relationship
of alloxan-diabetes and tumor growth. Cancer Res., 15, 626.
GRAHAM, S. (1986). Hypothesis regarding caloric intake in cancer
development. Cancer, 58, 1814.
GREENBERG, N.J., TZAGROURNIS, M. & GRAVES, T.M. (1968).
Stimulation of insulin secretion in man by medium chain trig-
lycerides. Med. Clin. Exp., 17, 796.
HARAN-GERA, N., BEN YAACOV, M. & PELED, A. (1977).
Immunologic characteristics in relation to high and low
leukomogenic activity of radiation leukemic virus variants. J.
Immunol., 118, 600.
HARPER, H.A. (1965). Metabolism of fat. In Review ofPhysiological
Chemistry, Wong, R.K.L. & VanBruggen, J.T. (eds) p. 223. Los
Altos, CA: Blackwell Scientific Publications.
HEMS, G. (1978). The contribution of diet and childbearing to breast
cancer rates. Br. J. Cancer, 37, 974.
HEUSON, J.C. & LEGROS, N. (1970). Effect of insulin and alloxan on
growth of the mammary carcinoma in vivo. Eur J. Cancer, 6, 349.694 D. YAM et al.
HEUSON, J.C., LEGROS, N. & HEIMANN, R. (1972). Influence of
insulin administration on growth of 7,12 dimenthyl-benz(a)-
anthracene mammary carcinoma in intact, oophorectomized and
hypophysectomized rats. Cancer Res., 32, 233.
HINDS, M.W., KOLONEL, L.N., LEE, J. & HANKIN, J.H. (1982).
Dietary cholesterol and lung cancer risk among men in Hawaii.
Am. J. Clin. Nutr., 37, 192.
HOBBS, C.B. & MILLER, A.L. (1966). Review of endocrine syndromes
associated with tumors of non endocrine origin. J. Clin. Pathol.,
19, 119.
HYRAYAMA, T. (1978). Epidemiology of breast cancer with special
reference to the role of diet. Prev. Med., 7, 173.
JEHL, J.A., MAYER, J. & MCKEE, R.W. (1955). Influence of the
hereditary obese hyperglycemic syndrome of alloxan diabetes on
the survival of mice with Erlich ascites carcinoma. Cancer Res.,
15, 341.
KARK, J.D., SMITH, A.H. & HAMES, C.G. (1980). The relationship of
serum cholesterol to incidence of cancer in Evans Country, Geor-
gia. J. Chronic Dis. 33, 311.
KESLER, I.I. (1970). Cancer mortality among diabetes. J. Natl Inst.,
44, 683.
KOLONEL, L.N., HANKIN, J.H., LEE, J., CHU, S.Y., NOMURA, A.M.Y.
& HINDS, M.W. (1981). Nutrients intake in relation to cancer
incidence in Hawaii. Br. J. Cancer, 44, 332.
LINSCHEER, W.G., SLONE, D. & CHALMERS, T.C. (1967). Effects of
octanoids on serum levels of free fatty acids, insulin and glucose
in patients with cirrhosis and in healthy volunteers. Lancet, i,
593.
LUNDHOLM, K., HOLM, G. & SCHRESTEN, T. (1978). Insulin resis-
tance in patients with cancer. Cancer Res., 38, 4665.
LUPULESCU, A. (1983). Glucagon control of carcinogenesis. Endo-
crinology, 113, 527.
MCMICHAEL, A.J., JENSEN, O.M. & PARKIN, M.D. (1984). Dietary
and endogenous cholesterol and human cancer. Epidemiol. Rev.,
6, 192.
MILLER, A.B., KELLY, A., CHOI, N.W. & 7 others (1978). A study of
diet and breast cancer. Am. J. Epidemiol., 107, 499.
MOUNTJOY, K.G., FINLAY, G.J. & HOLDAWAY, I.M. (1987). Abnor-
mal insulin reception down regulation and dissociation of down
regulation from insulin action in cultured human tumor cells.
Cancer Res., 47, 6500.
MOUNTJOY, K.G., HOLDAWAY, I.M. & FINLAY, G.J. (1983). Insulin
receptor regulation in cultured human tumor cells. Cancer Res.,
43, 4537.
NRC (1978). Nutrients Requirements of Laboratory Animals, 3rd edn.
National Academy of Science: Washington, DC.
PAVELIC, K., BOLANCA, M., VICEK, N., PAVELIC, J., MAROTTI, T. &
VUK-PAVOLIC, S. (1982a). Carcinomas of the cervix and corpus
uteri in human: stage-dependent blood levels of substance (s)
immunologically cross reactive with insulin. J. Nati Cancer Inst.,
68, 891.
PAVELIC, K., ODAVIC, M., HRSAK, I. & VUK-PAVLOVIC, S. (1982b).
Correlation of substance (s) immunologically cross-reactive with
insulin in Hodgkin's lymphoma patients. Cancer Lett., 17, 81.
PAVELIC, K. & PAVELIC, M. (1981). Insulin and glucagon secretion
by renal adenocarcinoma. Cancer, 48, 98.
PAVELIC, K. & SLYJEPCEVIC, M. (1978). Growth of a thymoma in
diabetic mice treated with insulin. Eur. J. Cancer, 14, 675.
PAVELIC, K. SLYJEPCEVIC, M., PAVELIC, J. & 4 others (1979).
Growth and treatment of Erlich tumor in mice with alloxan
induced diabetes. Cancer Res., 39, 1807.
PAVELIC, K. & VUK-PAVLOVIC, S. (1983). C peptides does not
parallel increases of serum levels of substances immunologically
cross-reactive with insulin in non-Hodgkin's lymphoma patients.
Blood, 61, 925.
PENNOCK, C.A., MURPHY, D., SELLERS, J. & LONGDON, K.J.
(1973). A comparison of autoanalyser methods for the determina-
tion of glucose in blood. Clin. Chim. Acta, 48, 193.
PUCKITT, C.L. & SHAGLETON, W.W. (1972). The effect of induced
diabetes on experimental tumor growth in mice. Cancer Res., 32,
789.
RERUP, C.C. (1968). Spontaneous remission of alloxan-diabetes in
mice. Diabetologia, 4, 312.
ROSE, G. & SHIPLEY, M.S. (1980). Plasma lipids and mortality: a
source of error. Lancet, i, 523.
SALZBERG, D.A. & GRIFFIN, A.C. (1952). Inhibition of Azo dye
carcinogenesis in the alloxan diabetic rat. Cancer Res., 12, 294.
SHAFIC, S.M. & LIOTTA, L.A. (1980). Formation of metastasis by
human breast carcinoma cells MCA.7 in nude mice. Cancer, 11,
81.
SHAPOT, V.S. (1972). Some biological aspects of the relationship
between the tumor and the host. Adv. Cancer Res., 15, 253.
SIEDEL, J., HAGELE, E.O., ZIEGENHORN, J. & WAHLEFED, A.W.
(1983). Reagent for the enzimatic determination of serum total
cholesterol with improved lipolytic efficiency. Clin. Chem., 29,
1075.
SMITH, L.L., SMART, V.B. & ANSARI, G.A.S. (1979). Mutagenic
cholesterol preparations. Mutation Res., 68, 23.
STOLAR, M.W. (1988). Atherosclerosis in diabetis. The role of
hyperinsulinemia. Metab. Clin. Exp., 37, Suppl.l, 1.
SZEPSENWOL, J. (1966). Carcinogenic effect of cholesterol in mice.
Proc. Soc. Exp. Med. Biol., 121, 168.
YAARI, S., GOLDBOURT, V., EVEN ZOHAR, S. & NEUFELD, H.N.
(1981). Associations of serum high density lipoprotein and total
cholesterol with total cardiovascular study of 10000 man. Lancet,
i, 1011.
YOSHINOBU, S., KASAI, K., HIRAIVA, M. & 4 others (1985). Mono-
layer cell culture of human insulinoma and in vitro studies of
regulatory mechanisms on insulin release. Dokkyo J. Med. Sci.,
12, 149.